Overview

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Status:
RECRUITING
Trial end date:
2026-07-04
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.
Phase:
PHASE1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated